Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis

IntroductIon
IgG directed against the α-isoform of glial fibrillary acidic protein (GFAP-IgG) predicts a distinct corticosteroid-responsive meningoencephalomyelitis termed autoimmune GFAP astrocytopathy, when detected on cerebrospinal fluid (CSF). 1 Optic disc oedema and tremor are common accompaniments. The MRI hallmark is a striking linear perivascular enhancement radially oriented around the ventricles (radial enhancement), while the myelitis component is generally associated with a longitudinally extensive T2 lesion on spinal cord MRI, similar to that typically encountered in aquaporin-4-IgG (AQP4-IgG) related myelitis. [1] [2] [3] We compared the clinical, laboratory and MRI features of GFAP-IgG and AQP4-IgG related myelitis.
MaterIals and Methods
Patient ascertainment
We retrospectively identified GFAP-IgG seropositive patients seen at the Mayo Clinic ( 1 January 2000 to 31 December 2017). Inclusion criteria were as follows: (1) serum/CSF demonstrating GFAP pattern by indirect immunofluorescence with GFAPα specificity confirmed by cellbased assay, as previously described; 1 (2) first myelitis episode; (3) serum sample negative for myelin oligodendrocyte glycoprotein-IgG (MOG-IgG) and AQP4-IgG using previously described methodology 4 5 ; (4) adequate clinical data available. Nine patients with GFAP-IgG myelitis were included in a prior report. 1 Two patients with dual positivity in serum for AQP4-IgG and GFAP-IgG were excluded. Medical records were reviewed and compared with 41 patients from a previously identified cohort of AQP4-IgG seropositive patients at the first episode of clinical myelitis who tested negative for GFAP-IgG (41 tested) and MOG-IgG (13 tested). 5 Improvement was defined as subjective improvement reported by the patient with objective improvement confirmed by the physician.
neuroimaging
All available MRI sequences obtained within 4 months of myelitis onset were reviewed by one neurology investigator (ES/EPF) and one neuroradiologist (TJK/ KNK/PPM) as described previously. 5 Consensus was achieved in situations of disagreement.
statistical analysis
Wilcoxon rank-sum test or χ 2 /Fisher's exact test was used as appropriate for comparison (JMP 8.0 software).
results
Fifty-four patients with myelitis were included:
GFAP-IgG positive, 13; AQP4-IgG positive, 41. Clinical, laboratory and MRI characteristics are summarised and compared in table 1.
All GFAP-IgG myelitis cases had extraspinal symptoms/signs simultaneously or preceding myelitis onset, including headache, 10; tremor, 9; encephalopathy, 9; optic disc oedema, 8; sleep disturbances, 4; dysautonomia, 4; speech disturbances, 3; photophobia/blurred vision, 3; abnormal startle response, 3; dizziness, 2; and incoordination, 2. Myelitis was the predominant neurological manifestation in three patients (23%). A recent history of weight loss (median (range): 20 (15-80) pounds) in the context of viral-like prodromes was common (62%) in autoimmune GFAP astrocytopathy. Conversely, intractable nausea and vomiting with or without hiccups constituted the prodromal symptoms in eight (20%) patients with AQP4-IgG myelitis. A concomitant neoplasm was detected in 3/13 (23%) patients with GFAP-IgG myelitis: multiple myeloma, 1; frontal sinus squamous cell carcinoma, 1; and gastrointestinal carcinoid, 1. GFAP-IgG was detected in: CSF, 8; serum, 2 (each had no CSF available); or both, 3. Seven had serial samples, of which four (57%) remained persistently positive (median positivity duration, 13.5 months; range 4-60).
neuroimaging
Spinal cord MRI was available in 10 GFAP-IgG and 31 AQP4-IgG positive cases (1 and 3 patients received corticosteroids before MRI, respectively).
Comparison of the MRI findings is illustrated in figure 1 . In GFAP-IgG myelitis, the T2-hyperintense signal appeared fainter with ill-defined margins compared with AQP4-IgG myelitis although direct comparison of signal intensity was not performed. Cauda equina enhancement/ thickening was observed in two with GFAP-IgG. Hallmark brain MRI 'radial enhancement' was detected in 10/12 (83%) GFAP-IgG cases.
treatment and outcome
All GFAP-IgG positive patients received high-dose intravenous methylprednisolone for 3-5 days with initial clinical response (partial or complete) in 100%, while plasma exchange was often necessary for AQP4-IgG myelitis (15/34 (44%)). Eleven patients with GFAP-IgG myelitis received maintenance oral corticosteroids. Median follow-up duration was 30 months (range 15-199). After immunotherapy, improvements were noted in spinal cord MRI abnormalities (8) and CSF parameters (8/8 with follow-up lumbar puncture). Clinical recurrence occurred in nine patients with GFAP-IgG myelitis (six during and two after corticosteroid maintenance/taper, one spontaneously) and some had residual disability (one developed spinal cord atrophy after 4 years). At last follow-up, 11 patients were receiving chronic immunosuppression (mycophenolate, 6; cyclophosphamide, 1; azathioprine, 1; oral steroids, 2) and 1 was stable without immunotherapy. Among AQP4-IgG 38 underwent chronic immunosuppression (oral steroids, 27; azathioprine, 23; mycophenolate, 10; rituximab, 9). Median follow-up was 35.5 months (range 4-163).
dIscussIon
Despite some overlapping features, GFAP-IgG related myelitis has important differences from AQP4-IgG related myelitis in its clinical presentation, CSF findings and MRI characteristics.
Myelitis occurs in up to 68% of those with autoimmune GFAP astroctyopathy, 3 develops more insidiously than AQP4-IgG myelitis and extraspinal symptoms/signs of autoimmune GFAP astrocytopathy usually coexist.
1-3 Viral-like prodromal symptoms were more common (92%) than previously reported. 2 3 By contrast, AQP4-IgG seropositive myelitis was occasionally preceded by symptoms of area postrema syndrome. Bowel/bladder dysfunction was the most common symptom with GFAP-IgG myelitis, while numbness and weakness often followed by tonic spasms predominated in AQP4-IgG group. Notably, sensory level and Lhermitte's phenomenon were usually absent with GFAP-IgG myelitis.
Spinal cord MRI T2 lesions were commonly longitudinally extensive (≥80%) and centrally located on axial images in both groups, consistent with prior reports. CSF findings were similarly inflammatory in both groups although oligoclonal bands (frequently transient) were more common with GFAP-IgG.
GFAP-IgG
patients usually showed improvement in clinical, radiologic and CSF abnormalities after corticosteroid administration and worsened with taper. While similar findings were reported in European patients, a less therapy-responsive form was more frequent among Asians. 2 3 The proportion of wheelchair-bound at last follow-up did not differ between the two groups, emphasising the need for early and sufficient immunosuppression to prevent long-term disability in GFAP-IgG myelitis.
Our study is limited by small sample size, retrospective design and lack of standardised outcome measures. Two GFAP-IgG positive cases had only serum available for testing but both had 
